Zürich (ots) - Prionics announced the acquisition of
CEDI-Diagnostics. The Dutch firm is a spin-off from the world-famous
Wageningen University and Research Centre (Wageningen UR). Through
the purchase of CEDI, Prionics will acquire a substantial number of
new products and gain rights to commercialize developments made by
the research centre. Prionics and Wageningen UR have additionally
agreed on a strategic partnership for the development of future
innovations in farm animal diagnostics.
With this acquisition, the successful Swiss company Prionics has
accomplished several objectives. "We have acquired a firm with tests
proven on the market and we gain access to future developments of a
unique global research centre", says Dr Markus Moser, co-CEO of
"The Animal Science Group of Wageningen UR, a recognized leader in
the field of animal disease control, will contribute further
potential for innovation to Prionics", comments Dr. Bruno Oesch,
co-CEO and Head of Research & Development at Prionics AG.
The products made by CEDI include tests for the early diagnosis of
foot and mouth disease or swine fever. "The CEDI products are
excellent tests which make an ideal addition to our existing
portfolio of farm animal diagnostics", says Ernst Zollinger, Head of
Marketing & Sales at Prionics AG.
Terms of the agreement include that Wageningen UR will acquire a
stake in Prionics. Further details are not disclosed.
CEDI-Diagnostics is a globally active company in the field of farm
animal diagnostics. The Dutch firm is a spin-off from the Animal
Science Group of Wageningen University. CEDI Diagnostics supplies
more than twenty products for the early detection of diseases in farm
animals. The product portfolio includes tests for the diagnosis of
BSE, foot and mouth disease, BVDV (Bovine Virus Diarrhoea Virus) and
classical swine fever. With some 20 employees, the business, founded
in 2001, serves customers in over 60 countries.
About Wageningen UR
Wageningen UR is a collaboration between Wageningen University,
the Van Hall Larenstein School of Higher Professional Education and
specialized research institutes in areas such as food and food
production, plant, animal, environment and agricultural economics.
With over 6000 employees and 9000 students, the business makes an
active contribution to the resolution of scientific, social and
economic problems in the life science sector. Wageningen UR works
closely together with governments, institutions, companies and the
general public. Within Wageningen UR, Wageningen Business Generator
is responsible for the spin off companies and is positioned to manage
and commercialize corporate intellectual property.
The world leader in the diagnosis of BSE and other prion diseases
Prionics was founded in 1997 as a spin-off from Zurich University. At
its headquarters in Zurich, Prionics develops and markets diagnostic
products for the early diagnosis of farm animal diseases. The company
places its main focus on diseases which are transmissible from
animals to human beings and thereby contributing to an improvement to
food safety. In October 2005 Prionics acquired Pfizer Animal Health's
Diagnostic portfolio. The recipient of the Swiss Economic Award 2002
as "Company of the year" and winner of the European Biotech Award
2004 for Excellence in Biotech Business; Prionics is driving its
business through a combination of outstanding research, high-quality
products and innovative marketing solutions.
ots Originaltext: Prionics AG
Director of Corporate Communications
Bouke de Vos
Press Officer Wageningen UR
For Information on CEDI and Wageningen UR please visit:
www.cedi-diagnostics.com and www.wbg.wur.nl